Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Insurer Incentives For Lower-Cost HIV Drugs Not Seen As Significant Threat For Gilead, ViiV

Nov 13 2018

• By Joseph Haas

Digital illustration of HIV Virus in Blood Stream in color background

Related Content

HIV Market Snapshot: Gilead's Biktarvy Set To Soar, But ViiV May Win In The End

Apr 18 2018

Express Scripts Rewards Low List-Priced Brands In 2019 Formulary, Retains Focus On Rebates

Aug 07 2018

Gilead’s Yescarta Growth Continues, But Momentum Slowed

Oct 25 2018

Mylan Plans To Compete In US HIV Market With Two Fixed-Dose Combos

Mar 05 2018

How Will Novel Agents Impact The HIV Market?

Apr 17 2018

Related Companies

Gilead Sciences, Inc.

ViiV Healthcare

Viatris Inc.

Merck & Co., Inc.

GSK plc

Express Scripts Holding Company

Johnson & Johnson

Additional Topics

Pricing Strategies Commercial Business Strategies Infectious Diseases BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window